-
Je něco špatně v tomto záznamu ?
Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up
L. Fila, L. Valentova Bartakova, A. Grandcourtova, M. Marel, R. Drnek, A. Bilkova, M. Macek, P. Drevinek
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
27226150
DOI
10.5507/bp.2016.029
Knihovny.cz E-zdroje
- MeSH
- aktivátory chloridových kanálů terapeutické užití MeSH
- aminofenoly terapeutické užití MeSH
- chinolony terapeutické užití MeSH
- cystická fibróza farmakoterapie patofyziologie MeSH
- dospělí MeSH
- lidé MeSH
- mladý dospělý MeSH
- následná péče MeSH
- usilovný výdechový objem fyziologie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years together with an evaluation of ivacaftor therapy in one patient with an initial FEV1 less than 40% of predicted value. METHODS: Data on development of clinical status and sinopulmonary-related therapies were obtained from patient health records during ivacaftor treatment lasting for up to six years and were compared with an equivalent period before ivacaftor administration. RESULTS: Five CF adults with a median age 28.6 years (range 21.4-35.6 years) with median FEV1 45% pred. (range 16-85% pred.) were included in the study. Four subjects were also participants in the STRIVE and PERSIST studies. Altogether, twenty-four patient-years of ivacaftor treatment were analyzed. The median FEV1 decline per year decreased from -4.5 to -0.9% pred. (P = 0.043). Reduction in number of days on antibiotic treatment and hospital stays was 21% (P < 0.001) and 75% (P = 0.003), respectively. Improvement and stabilization of lung function was observed for up to six years of treatment. In a patient with severe airway obstruction, an increase in the FEV1 value (30.4% from baseline) was documented during the first twelve months of treatment. CONCLUSION: Ivacaftor therapy resulted in improved and stabilized lung function in up to six years of treatment with a reduction in number of days on antibiotic treatment and hospital stays. Its efficiency was also displayed in a patient with severe airway obstruction.
Cystic Fibrosis Centre University Hospital Motol Prague Czech Republic
Division of Health Insurance University Hospital Motol Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17012968
- 003
- CZ-PrNML
- 005
- 20180320082020.0
- 007
- ta
- 008
- 170413s2016 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2016.029 $2 doi
- 035 __
- $a (PubMed)27226150
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Fila, Libor, $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic $d 1968- $7 ola2006345307
- 245 10
- $a Ivacaftor in cystic fibrosis adults: Czech experience with six years of follow-up / $c L. Fila, L. Valentova Bartakova, A. Grandcourtova, M. Marel, R. Drnek, A. Bilkova, M. Macek, P. Drevinek
- 520 9_
- $a AIMS: Ivacaftor is a revolutionary treatment option for cystic fibrosis (CF) patients with G551D and other gating mutations. The aim of this study was to evaluate the clinical status of patients on ivacaftor who were followed for up to 6 years together with an evaluation of ivacaftor therapy in one patient with an initial FEV1 less than 40% of predicted value. METHODS: Data on development of clinical status and sinopulmonary-related therapies were obtained from patient health records during ivacaftor treatment lasting for up to six years and were compared with an equivalent period before ivacaftor administration. RESULTS: Five CF adults with a median age 28.6 years (range 21.4-35.6 years) with median FEV1 45% pred. (range 16-85% pred.) were included in the study. Four subjects were also participants in the STRIVE and PERSIST studies. Altogether, twenty-four patient-years of ivacaftor treatment were analyzed. The median FEV1 decline per year decreased from -4.5 to -0.9% pred. (P = 0.043). Reduction in number of days on antibiotic treatment and hospital stays was 21% (P < 0.001) and 75% (P = 0.003), respectively. Improvement and stabilization of lung function was observed for up to six years of treatment. In a patient with severe airway obstruction, an increase in the FEV1 value (30.4% from baseline) was documented during the first twelve months of treatment. CONCLUSION: Ivacaftor therapy resulted in improved and stabilized lung function in up to six years of treatment with a reduction in number of days on antibiotic treatment and hospital stays. Its efficiency was also displayed in a patient with severe airway obstruction.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a následná péče $7 D000359
- 650 _2
- $a aminofenoly $x terapeutické užití $7 D000627
- 650 _2
- $a aktivátory chloridových kanálů $x terapeutické užití $7 D065101
- 650 _2
- $a cystická fibróza $x farmakoterapie $x patofyziologie $7 D003550
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a usilovný výdechový objem $x fyziologie $7 D005541
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a chinolony $x terapeutické užití $7 D015363
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Valentová-Bartáková, Lucie $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic $7 xx0093360
- 700 1_
- $a Grandcourtová, Alžběta $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic; Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic $7 _AN064765
- 700 1_
- $a Marel, Miloslav, $u Department of Pneumology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic $d 1953- $7 nlk19990073527
- 700 1_
- $a Drnek, Radovan $u Division of Health Insurance, University Hospital Motol, Prague, Czech Republic $7 _AN077407
- 700 1_
- $a Bilkova, Alena $u Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic; Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Macek, Milan, $u Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic; Department of Biology and Medical Genetics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic $d 1961- $7 mzk2006348713
- 700 1_
- $a Dřevínek, Pavel, $u Cystic Fibrosis Centre, University Hospital Motol, Prague, Czech Republic. Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic. $d 1975- $7 xx0075827
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 2 (2016), s. 276-279
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20180320082038 $b ABA008
- 999 __
- $a ok $b bmc $g 1205364 $s 973741
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 160 $c 2 $d 276-279 $e 20160525 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20170413